What question did this study set out to answer?

This research aims to systematically assess and compare the toxicities associated with CAR-T therapy against standard treatment options for hematologic malignancies.

March 4, 2026BMC CancerOpen Access

Toxicities associated with CAR-T therapy compared with standard treatments in hematologic malignancies: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

AR alexandra porras ramirezUniversidad El Bosque AMAlejandro Rico MendozaUniversidad El Bosque LELiliana EncinalesUniversidad Metropolitana

Discussion

Member takes

Implication

Systematic review compares toxicities of CAR-T therapy with standard treatments, indicating unique immune-mediated risks.

Key Points

This research aims to systematically assess and compare the toxicities associated with CAR-T therapy against standard treatment options for hematologic malignancies.
Conducted a systematic review and meta-analysis.
Compared toxicities of CAR-T therapy and standard treatments, including chemotherapy, monoclonal antibodies, and allo-HSCT.
Analyzed outcomes such as cytokine release syndrome, neurotoxicity, prolonged cytopenias, and infections.
Performed random-effects analysis and subgroup analyses.
Assessed clinical heterogeneity and treatment management practices.
CAR-T therapy had significantly higher risks of severe CRS and ICANS compared to conventional chemotherapy (RR > 8).
Increased risk of prolonged cytopenias (RR 3.10) and serious infections (RR 2.00) compared to standard treatments.
Differences in toxicities were noted as comparator-dependent, with some modest overlaps in risks.
TRM showed no significant difference compared to most standard treatments.
Toxicity risk exhibited a biphasic pattern with early and late events.

Cite This Study

ramirez et al. (2026) studied this question.

synapsesocial.com/papers/69a7cd9dd48f933b5eeda255 https://doi.org/10.1186/s12885-026-15780-2

View Full Paper

Ask AI

Bookmark

March 4, 2026BMC CancerOpen Access

Toxicities associated with CAR-T therapy compared with standard treatments in hematologic malignancies: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

AR alexandra porras ramirezUniversidad El Bosque AMAlejandro Rico MendozaUniversidad El Bosque LELiliana EncinalesUniversidad Metropolitana

Discussion

Member takes

Implication

Systematic review compares toxicities of CAR-T therapy with standard treatments, indicating unique immune-mediated risks.

Key Points

This research aims to systematically assess and compare the toxicities associated with CAR-T therapy against standard treatment options for hematologic malignancies.
Conducted a systematic review and meta-analysis.
Compared toxicities of CAR-T therapy and standard treatments, including chemotherapy, monoclonal antibodies, and allo-HSCT.
Analyzed outcomes such as cytokine release syndrome, neurotoxicity, prolonged cytopenias, and infections.
Performed random-effects analysis and subgroup analyses.
Assessed clinical heterogeneity and treatment management practices.
CAR-T therapy had significantly higher risks of severe CRS and ICANS compared to conventional chemotherapy (RR > 8).
Increased risk of prolonged cytopenias (RR 3.10) and serious infections (RR 2.00) compared to standard treatments.
Differences in toxicities were noted as comparator-dependent, with some modest overlaps in risks.
TRM showed no significant difference compared to most standard treatments.
Toxicity risk exhibited a biphasic pattern with early and late events.

Cite This Study

ramirez et al. (2026) studied this question.

synapsesocial.com/papers/69a7cd9dd48f933b5eeda255 https://doi.org/10.1186/s12885-026-15780-2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark